SLC5A2 and metabolic dysfunction-associated steatohepatitis: The control of metabolic regulation through both FGF21-dependent and independent pathways points towards the multifaceted capacities of SGLT2 inhibitors, highlighting their potential as comprehensive strategies for the management of metabolic conditions such as MAFLD and NASH [204,207,208].